Company / Cash & Equivalents
ALX ONCOLOGY HOLDINGS INC Cash & Equivalents History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$48.8M
FY2022
5-year range
$48.8M / $434.2M
FY2020-FY2022
Trend
-88.8%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $434M to $49M over the past 2 years.
Based on SEC 10-K filings.
$49M in FY2022.
Declined from $434M to $49M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, cash & equivalents decreased 88.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $48.8M | -88.8% |
| FY2021 | $434.2M | +0.0% |
| FY2020 | $434.2M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026